|
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsor: | Qingdao University |
|---|---|
| Information provided by: | Qingdao University |
| ClinicalTrials.gov Identifier: | NCT01219465 |
Purpose
The purpose of this study is to determine whether umbilical cord Mesenchymal Stem Cells of treatment for initial type 1 diabetes is safe and effective.
| Condition | Intervention | Phase |
|---|---|---|
|
Diabetes Mellitus Diabetes Mellitus, Type 1 Mesenchymal Stem Cells Umbilical Cord |
Biological: umbilical cord mesenchymal stem cells |
Phase 1 Phase 2 |
| Study Type: | Interventional |
| Study Design: | Allocation: Non-Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | Safety and Efficacy of Umbilical Cord Mesenchymal Stem Cells Infusion for Initial Type 1 Diabetes |
| Estimated Enrollment: | 50 |
| Study Start Date: | September 2010 |
| Estimated Study Completion Date: | December 2012 |
| Estimated Primary Completion Date: | September 2012 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: umbilical cord mesenchymal stem cells
Intravenous infusion of ex vivo cultured umbilical cord mesenchymal stem cells
|
Biological: umbilical cord mesenchymal stem cells
Transfusion of the umbilical cord mesenchymal stem cells (2 x 107 cells) intravenously.
Other Name: mesenchymal stem cells
|
Type 1 diabetes mellitus (T1DM)is characterized by the autoimmune destruction of the pancreatic β cells.Patients require multiple daily insulin injections throughout their lives as well as close monitoring of their diet and blood sugar levels to prevent complications. The investigators hope umbilical cord Mesenchymal Stem Cells could not only address the need for β-cell replacement but also control of the autoimmune response to β cells.
Eligibility| Ages Eligible for Study: | 3 Years to 35 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations| China, Shandong | |
| Stem Cell Research Center of Medical School Hospital of Qingdao University | |
| Qingdao, Shandong, China, 266003 | |
| Study Director: | Yangang Wang, MD Phd | The Affiliated Hospital of Medical College of Qingdao University |
More Information
| Responsible Party: | Wang, Yangang MD, Stem Cell Research Center of Medical School Hospital of Qingdao University |
| ClinicalTrials.gov Identifier: | NCT01219465 History of Changes |
| Other Study ID Numbers: | MSCT1DM003 |
| Study First Received: | October 12, 2010 |
| Last Updated: | October 12, 2010 |
| Health Authority: | China: Ministry of Health |
|
Diabetes Mellitus Diabetes Mellitus, Type 1 mesenchymal stem cells Umbilical cord |
|
Diabetes Mellitus Diabetes Mellitus, Type 1 Glucose Metabolism Disorders Metabolic Diseases |
Endocrine System Diseases Autoimmune Diseases Immune System Diseases |